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Abstract
Background: Population impact measures (PIMs) have been developed as tools to help policy-
makers with locally relevant decisions over health risks and benefits. This involves estimating and
prioritising potential benefits of interventions in specific populations. Using tuberculosis (TB) in
India as an example, we examined the population impact of two interventions: direct observation
of therapy and increasing case-finding.
Methods: PIMs were calculated using published literature and national data for India, and applied
to a notional population of 100 000 people. Data included the incidence or prevalence of smear-
positive TB and the relative risk reduction from increasing case finding and the use of direct
observation of therapy (applied to the baseline risks over the next year), and the incremental
proportion of the population eligible for the proposed interventions.
Results: In a population of 100 000 people in India, the directly observed component of the
Directly Observed Treatment, Short-course (DOTS) programme may prevent 0.188 deaths from
TB in the next year compared with 1.79 deaths by increasing TB case finding. The costs of direct
observation are (in international dollars) I$5960 and of case finding are I$4839 or I$31702 and
I$2703 per life saved respectively.
Conclusion: Increasing case-finding for TB will save nearly 10 times more lives than will the use
of the directly observed component of DOTS in India, at a smaller cost per life saved. The
demonstration of the population impact, using simple and explicit numbers, may be of value to
policy-makers as they prioritise interventions for their populations.
Background
Tuberculosis (TB) is a major global public health prob-
lem. Reducing the burden of morbidity and mortality due
to TB relies on identifying the treatments and preventive
measures of greatest impact, and communicating this
information to decision-makers so that the most appro-
priate policies are implemented.
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BMC Medicine 2006, 4:35 http://www.biomedcentral.com/1741-7015/4/35We have previously described a series of population
impact measures (PIMs) to describe the population
impacts of risks and benefits [1-3]. These are measures of
absolute risk and are based on previous methods for
describing clinical and population impacts. They provide
local meaning to an otherwise confusing mixture of
generic evidence and local statistics, helping policy-mak-
ers to identify and prioritise the potential benefits of inter-
ventions in their own population. PIMs are simple to
compute, and contain the elements to which policy-mak-
ers need to pay attention in the commissioning or
improvement of services. They are designed as useful
additions to the generic measures of illness burden, from
which they differ in having event-specific outcomes rather
than generic outcomes such as the quality-adjusted life
year (QALY) or the disability-adjusted life year (DALY).
The World Health Organization (WHO) has promoted
the Directly Observed Treatment, Short-course (DOTS)
strategy, which comprises five elements, (political com-
mitment, case detection using sputum microscopy, stand-
ardised short-course chemotherapy, regular drug supply,
and a standardised recording and reporting system).
These elements incorporate direct observation of treat-
ment but exclude active case finding [4]. DOTS pro-
grammes may differ in the emphasis placed on the five
elements, and may incorporate additional features[5]. In
India, the Revised National Tuberculosis Control Pro-
gramme gives considerable emphasis to directly observed
treatment, so that it is now one of the five main elements
[6]. Some authors have suggested that case finding is
underemphasised as a global TB control strategy [7-11],
and that directly observed therapy may be overempha-
sised[5,12]. Case-finding may be "active" or
"enhanced"[11]; we did not specify which of these we
include under our general category of increased case-find-
ing, as this will vary according to local conditions. In this
study, the utility of using PIMs to describe the population
impact of the directly observed component of DOTS was
compared with that of increased case-finding, using India,
where TB provides a major health burden, as an exam-
ple[13].
Methods
To describe the impact of preventive and treatment inter-
ventions, the number of events prevented in a population
(NEPP) is defined as "the number of events prevented by
the intervention in your population over a defined time
period" [2]. NEPP extends the number needed to treat
(NNT) beyond the individual patient to a specific popula-
tion. The components of the calculations (see Appendix
for the formulae) are: (i) population denominator (size of
the population); (ii) proportion of the population with
the disease; (iii) the incremental proportion of the dis-
eased population eligible for the proposed intervention
(the latter requires the actual or estimated proportion
who are currently receiving, and are compliant with, the
interventions, subtracted from best practice goal from
guidelines or targets); (iv) baseline risk (the probability of
the outcome of interest in this or similar populations);
and the(v) relative risk reduction (RRR) associated with
the intervention. Confidence intervals (CIs) for the meas-
ures were obtained using simulation methods http://
www.phsim.man.ac.uk/. The calculations were made
using published data (each source is referenced in the
Results section).
Data from the paper by Baltussen et al[14] were used to
calculate the costs, which are reported in international
dollars (I$). Direct observation of therapy requires 40
clinic visits for supervision (24 in the intensive and 16 in
the continuation phase) rather than 4 (1 initial and 3 for
progress monitoring) for unobserved treatment. Each
clinic visit costs I$3.85. Each TB smear test for those iden-
tified by case finding costs I$1.14, and we multiplied this
by the prevalence of symptoms in the population (to
reflect that increased case-finding would occur among
those who are symptomatic). We do not have an estimate
of the costs of detecting those who are symptomatic in
order for them to have a sputum smear for diagnosis, as
the way in which cases are detected will differ depending
on the setting and on whether the case finding is "active"
or "enhanced"[11]. However, we doubled the cost of the
smears to allow for the costs of the case finding to detect
symptomatic people who will subsequently have a smear,
and also added the treatment costs for the cases of smear-
positive TB identified by the case-finding process (drug
costs at I$7.84 plus four clinic visits per patient).
Results
The published data show that 45% of identified TB
patients in India are covered by the DOTS programme[15]
However, only an estimated 50% of smear-positive TB
cases in India are identified by the current passive case-
finding approach[13]. The benefit of increasing this by a
further 20% (or 40% of the currently unidentified cases)
was estimated, as this is consistent with the national and
global target of detecting 70% of smear-positive
cases[6,13], and is a conservative estimate of the propor-
tion of undetected cases that might be found through case
finding[11,16]. The added benefit of the directly observed
component of DOTS on cure and completion rates has
been estimated in a systematic review as 6%, which is the
figure used in our study, although this was not statistically
significantly different from no benefit[12]. We assumed
that this benefit would translate to a similar reduction in
case fatality. Six-month case fatality for treated TB was esti-
mated in the original MRC trial of the treatment of TB as
7.3% and for untreated TB 27%, with a reduction of 73%
from treatment,[17] and are consistent with a reportedPage 2 of 6
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that only 71% of patients with TB would complete treat-
ment in the absence of the DOTS programme, taken from
the "cure plus treatment completion" figures of the con-
trol groups in the Cochrane review[12]. This is consistent
with the 76% quoted elsewhere [19] Table 1 demonstrates
that the current direct observation of the DOTS pro-
gramme would, on average, produce a reduction of 0.188
deaths from TB for each 100 000 people in the population
in a year. If the identification rate of TB was increased by
20%, using increased case-finding, and 71% of these peo-
ple completed treatment, there would be a reduction of
1.79 deaths from TB for each 100 000 people in the pop-
ulation in a year, nearly 10 times the numbers of deaths
saved by direct observation of therapy.
Costs
The cost of direct observation for 36 extra clinic visits is
I$138.6 per patient. Table 1 shows that there are 43
smear-positive cases per 100 000 population in a year,
thus the cost of direct observation for these 43 cases is
I$5960, resulting in a cost of I$31702 per life saved.
For case finding, we estimated that 2% of the population
may be symptomatic (from previous figures of 1.2–6.7%
symptomatic people in possibly similar popula-
tions[11,16]), hence requiring 2000 smears. This may be
a conservative estimate, as Baltussen estimates that only
30 smears need to be taken to find one case, whereas we
estimated it would take 2000 smears to find 12 cases
(40% of the 32 undiagnosed in our population of 100
000), or 167 smears to find one case. The drug costs and
4 clinic visits total I$23.24 for each of the 12 identified
cases. The cost of case finding is thus estimated to be
I$4839, or I$2703 per life saved (table 2).
Discussion
This study shows that, given the parameters used, increas-
ing case finding by 20% would lead to nearly 10 times the
numbers of deaths saved by the current direct observation
of therapy in India. This is due to a greater RRR, applied to
a higher baseline case-fatality, hence producing a larger
absolute benefit. The analysis clearly shows that, based on
the assumptions made, improving case-finding for TB will
save far more lives than maximizing the use of the directly
observed component of DOTS among currently identified
cases in India. This has obvious implications for health
decision-makers. Although the DOTS program does
encourage better case detection, it does not include active
or enhanced case-finding [5,6,20]. Our findings concur
with those who feel that case finding should receive more
attention [7,21,22], and that a careful approach to exam-
ining the benefits of different aspects of DOTS pro-
grammes should be encouraged[5].
There are several different strategies for increasing case-
finding, and the choice should depend on local factors
such as disease prevalence, adequacy of training of health-
care workers and willingness of the infected population to
seek care for symptoms[11]. The benefits of active, passive
or enhanced case-finding among general, high-risk, and
symptomatic populations have been reviewed in depth by
Golub et al[11].
The calculations made in this study depend on the accu-
racy of the data used. Each estimate is subject to potential
error, and ideally, each population should obtain its own
data in order to produce accurate estimates of population
impact of risks and interventions. The literature-based
estimates of RRR are also open to question. Our use of the
baseline risk of death from treated and untreated TB uses
old trial data, although the treated risk is consistent with
recently published data of death rates of 4.4% among
DOTS-registered cases in countries with high TB bur-
den[13]. We applied the cure rate of the systematic review
of DOTS therapy to the case fatality, and this may be open
to question. An updated Cochrane Review was published
in 2006[23], which came to the same conclusion about a
non-significant 6% difference in the outcome cured or
completed treatment. There were insufficient numbers to
allow analysis of case fatality, although four of the
included trials did include mortality as an outcome meas-
ure. The results of the calculations depend on the various
assumptions made. For example, changing the estimate of
TB treatment completion would have changed the
number of deaths prevented, but is unlikely to have
changed the ranking of benefit between increasing case-
finding and direct observation of treatment. Thus it is
important to obtain relevant local data, apply the
approach to different populations and population sub-
groups, and to test the robustness of the estimates to var-
ying the assumptions. For example, in a population where
case finding is already extensive, costs per case detected
are likely to be higher, and thus maximizing the use of
directly observed therapy could have the greater impact.
The confidence intervals were made taking into account
the potential variability of the estimates used; however,
changing the estimates used for each of the components
of the PIMs themselves has additional potential to influ-
ence the results. This can be explored by recalculating the
measures using different estimates as appropriate to par-
ticular local settings. To assist potential users, we have
developed a public access website that automatically cal-
culates both the PIMs and their confidence intervals http:/
/www.phsim.man.ac.uk/.
We did not include the impact of transmission dynamics
on the rest of the population in our calculations, as this
would add considerably to the complexity of thePage 3 of 6
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observation and improved case-finding, the lack of atten-
tion to transmission dynamics will underestimate the rel-
ative benefit of improved case-finding, as the resulting
early intervention is likely to be more effective than the
later attempt to improve therapy adherence. The decision
to restrict the analysis to smear-positive cases was based
on the better accuracy of this measure of disease burden,
although it will underestimate the benefit of treatment on
extrapulmonary TB. We do not wish to claim false accu-
racy for the results presented; however, they do use the
best available data, are easy to compute and produce
results that are easy to understand. The level of accuracy
should be adequate for most policy decisions, and is pref-
erable to making decisions in the absence of estimates of
population benefit.
If PIMs prove useful where relevant data exist, then this
could stimulate better collection and use of health data in
situations where there are currently too few data to enable
reasonable calculations. Similarly, the use of PIMs with
confidence intervals enables policy-makers to be explicit
about the uncertainties they face.
The measures can be used to compare between popula-
tions, in which case standardization for age, sex, ethnicity
and socioeconomic status may be required. The measures
can also be used to compare between segments of a pop-
ulation, in which case the potential for an intervention to
reduce health inequalities and increase equity within a
population can be explored[3].
For ease of presentation, the population denominator we
used was 100 000 adults; however, one of the main bene-
fits of these measures is the ability to relate to local con-
text, hence policy-makers can make the calculations for
their own population denominator.
The addition of information on costs to the population
impact measures will also be important for policy makers,
and our estimated costs for the programme will allow
costs and their consequences to be calculated[24]. PIMs
differ from measures used in cost-effectiveness analyses by
not including life expectancy or the utility or valuation of
the health outcome. They thus produce outcomes
expressed as events rather than generic outcomes such as
QALY or DALY gained[25]. We have previously suggested
that the valuation of the events prevented should be per-
formed by the policy-maker in relation to the costs of the
intervention, once the measures have been produced [26].
Although our cost estimates are prone to error, they were
derived using previously published costs applied to this
simple model of health gain. They show that the pro-
gramme costs for the direct observation of therapy and the
Table 1: Number of deaths prevented among 100,000 people in India with direct observation of therapy and increased use of case 
finding
Direct observation of therapy Increase in TB case-finding
Population denominator 100 000 100 000
Incidence of smear-positive TB 0.00043* 0.00032†
Proportion of the diseased population eligible for the intervention: 
best practice goal minus current practice levels
All those identified are estimated to be subject to 
direct observation
0.40 (0.284)‡
Baseline risk (case fatality) 7.3% [17] 27% [17]
RRR from intervention 0.06 [12] 0.73 [17]
NEPP (deaths from TB prevented in the next year) 0.188§ (95% CI 0.014–0.294) 1.79¶ (95% CI 1.01–2.69)
NEPP, number of events prevented in the population; RRR, relative risk reduction; TB, tuberculosis.
The examples are based on a population of 100 000, but in reality the actual number and composition of the population to which the results are to 
be applied would be identified.
*Based on 57% DOTS case detection rate, or 43 per 100 000 per year [13]
†The estimated true incidence rate is 75 per 100 000[13], so 32 per 100 000 is the potential for case finding.
‡40% of cases identified by case detection; proportion of identified cases who will complete treatment = 71%, thus 0.40 × 0.71 = 0.284.
§100 000 × 0.00043 × 0.073 × 0.06 = 0.188.
¶100 000 × 0.00032 × 0.284 × 0.27 × 0.73 = 1.79.
Table 2: Costs of direct observation of therapy and increased use of case finding among 100 000 people in India
Direct observation of therapy Increase in TB case-finding
Extra TB smears for case detection (@I$2.28) N/A 2000
Number of extra clinic visits (@I$3.85) 36 per patient 4 visits for each of 12 new patients identified
Extra drug costs (@I$7.84) N/A For each of 12 new patients identified
Total cost (I$) 5960 4839
Cost per life saved (I$) 31702 2703
I$, international dollars; N/A, not applicable; TB, tuberculosis.Page 4 of 6
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gain is much greater for the detection of new cases. In fact,
our estimate of the health gain from direct observation
may be an overestimate, as the relative risk quoted was
not significantly different from no effect.
The data shown on TB control demonstrates the potential
benefit to policy-makers from the use of PIMs. There is
some evidence that the way in which health benefits are
framed impacts on the policy decisions reached[27],
although there is debate about the consistency of such an
effect[28]. We previously showed that although clinicians
were more influenced by benefit expressed as RRR than as
PIMs[29], public health professionals were more likely to
prioritise interventions based on the use of PIMs than on
the basis of more complex demonstrations of health gain
[26]. The evidence base on what are the most effective
methods of presenting health gains from interventions in
order to assist in policy-making is, however, weak. Health
policy requires more than merely demonstration of health
gain [30-32], as the complexity of policy-making includes
social and political drivers of decision-making, as well as
the need to take into account issues such equity, total
budget impact, total morbidity and disease severity.
Our method is considerably simpler than other modelling
exercises that have also examined the potential benefits of
case finding[7,8], and may compensate for this simplicity
by the increased ease of when making the calculations and
understanding the results. Both modelling and the calcu-
lation of PIMs have similar reliance on data availability
and accuracy. Our method is not intended to replace more
complex analyses of TB control[14], nor is it intended to
reflect adversely on the DOTS programme, which has
many components, of which direct observation is only
one. It is intended to show how to use local data to pro-
vide simple demonstrations of health benefit, which can
then be used in policy-making. We believe that it is worth
testing the hypothesis that simple demonstration of the
population health-gain consequences of interventions
will lead to the introduction of health policies that can
provide appropriate priorities to improve health in devel-
oping countries. This could be of marked benefit in TB, a
major threat to global health.
Conclusion
Increasing case-finding for TB will save nearly 10 times
more lives than will the use of the directly observed com-
ponent of DOTS in India, at a smaller cost per life saved.
The demonstration of the population impact, using sim-
ple and explicit numbers, may be of value to policy-mak-
ers as they prioritise interventions for their populations.
Appendix
Formula for calculating population impact measure
Number of events prevented in your population (NEPP) 
[2]
NEPP = n* Pd * Pe * ru * RRR
where n = population size, Pd = prevalence of the disease
in the population, Pe = proportion eligible for treatment,
ru = risk of the event of interest in the untreated group or
baseline risk, and RRR = relative risk reduction associated
with the treatment
In order to reflect the incremental effect of changing from
current to "best" practice and to adjust for levels of com-
pliance the proportion eligible for treatment Pe is
((Pb - Pt) * Pc
where Pt is the proportion currently treated, Pb is the pro-
portion that would be treated if best practice was adopted
and Pc is the proportion of the population that is compli-
ant with the medication.
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